NHAS
LXEO icon

Novo Holdings A/S’s Lexeo Therapeutics LXEO Stock Holding History

Novo Holdings A/S’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,122,581
Closed -$3.9M – 31
2025
Q1 		$3.9M Hold
1,122,581
– – 0.3% 25
2024
Q4 		$7.39M Hold
1,122,581
– – 0.45% 28
2024
Q3 		$10.1M Sell
1,122,581
-327,919
-23% -$3.91M 0.5% 30
2024
Q2 		$23.3M Sell
1,450,500
-187,798
-11% -$2.73M 1.25% 28
2024
Q1 		$25.7M Buy
1,638,298
+330,469
+25% +$5.17M 1.77% 23
2023
Q4 		$17.6M Buy
+1,307,829
New +$16.2M 1.08% 28

Other funds holding LXEO

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Novo Holdings A/S's LXEO Position: Q2 2025 in Review

Novo Holdings A/S sold out of Lexeo Therapeutics (LXEO) in Q2 2025, closing a stake of 1,122,581 shares — an estimated $3.9M sold.

Novo Holdings A/S first reported a position in LXEO in Q4 2023 and held it in 6 quarters. The position peaked at $25.7M in Q1 2024. 90 funds tracked by Wall St. Rank hold LXEO as of Q2 2025.

  • Novo Holdings A/S reported no remaining Lexeo Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Novo Holdings A/S sold 1,122,581 Lexeo Therapeutics shares in Q2 2025, an estimated $3.9M.
  • Novo Holdings A/S first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 6 quarters.
  • Novo Holdings A/S's Lexeo Therapeutics position peaked at $25.7M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2025.

Based on Novo Holdings A/S's 13F filing for Q2 2025, filed 14 Aug 2025.